This Week in Biotech: An FDA and CHMP Smackdown Ensues

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

With the SPDR S&P Biotech Index up 62% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies that made waves in the sector last week.

Just as in the previous weeks, this was another wild week for the volatile biotech sector. A quartet of bad-news items from the Food and Drug Administration and European Medicines Agency weighed heavily on a handful of companies, while two positive clinical trial results, an announced asset purchase, and a return of the buyout rumors for another struggling biotech stock attempted to even out the pessimism.

Today, we'll break a bit from tradition and focus on the five regulatory decisions that ruled the week to start, and in Part 2 of "This Week in Biotech," we'll examine those trials and deals that made headlines. First, though, let's have a look at the quartet of negative opinions and rejections that sent four companies lower at some point during the week, and end with one company that managed to get an A-OK from the FDA this week.

Misery loves company
Perhaps no rejection was more highly profiled this past week than that of the Food and Drug Administration's Division of Metabolism and Endocrinology Products, which on Tuesday declined to reinstate the Special Protocol Assessment for Amarin's (NASDAQ: AMRN  ) Vascepa in the ANCHOR trial. The news isn't a real shock for anyone who has been following Amarin's attempt to expand the uses of triglyceride-lowering drug, Vascepa, to a broader population with the FDA's panel concerned about long-term cardiovascular effects and efficacy of the drug. Because of this, Amarin is going to have no choice but to run a lengthy and costly cardiovascular outcomes study known as REDUCE-IT. Even if this trial turns out favorably, it'll still be three or more years before we know the results and Amarin will likely have used much of its existing cash on hand.

Joining Amarin in the corner with the dunce cap on is AMAG Pharmaceuticals (NASDAQ: AMAG  ) , which received a complete response letter (i.e., a rejection letter) for its supplemental new drug application for Feraheme. Currently, AMAG's Feraheme is approved to treat chronic kidney disease, but AMAG is seeking to expand its usage to all adult iron deficiency anemia patients. The FDA saw things differently, however, and noted that its trials didn't adequately establish the safety and efficacy of Feraheme for this expanded indication. The FDA's guidance to gain this all-adult IDA approval includes running additional trials that test for hypersensitivity/anaphylaxis and cardiovascular events, and trying out different dosing options and/or administration options. I doubt this is the last we'll see of Feraheme's sNDA, but we can probably move an adult-IDA indication to the back burner for the next year or two.

Jumping across the pond didn't help, either, with PTC Therapeutics (NASDAQ: PTCT  ) and even biopharmaceutical giant Novartis (NYSE: NVS  ) receiving negative opinions from the Committee for Medicinal Products for Human Use, or CHMP.

On Friday, PTC Therapeutics vacillated wildly after the CHMP announced a negative opinion on PTC's marketing authorization application for ataluren as a treatment for nonsense mutation Duchenne muscular dystrophy, or nmDMD. The move, though, wasn't a huge shock as PTC had been predominantly cautious about receiving the go-ahead to market its drug prior to completing its phase 3 nmDMD study. The results of that study are expected by mid-2015 with PTC anticipating a resubmission to CHMP sometime next quarter. While I would certainly prefer to wait for the broader-scale data here, any major sell-off may prove unwarranted on this negative opinion.

Similarly, Novartis' breakthrough therapy designated drug in the U.S., serelaxin, received no red carpet welcome in the EU with the CHMP also announcing a negative opinion on the acute heart failure drug. The CHMP noted that while there was some benefit in dyspnea (i.e., shortness of breath) relief over five days, clinical relevance could not be determined; nor could the effect of serelaxin within the first 24 hours. In addition, as FierceBiotech noted, the CHMP questioned the background treatments given to the patients in its acute heart failure study, and if that may have influenced the results. Although the European Medicines Agency isn't required to follow the opinion of its panel, the CHMP, it's looking very unlikely that an approval is around the corner and that further testing will need to be done if an EU approval is to occur. 

The lone bright spot
There was but one lone bright spot this week when it comes to regulatory decisions, and clinical-stage biopharmaceutical company CytRx (NASDAQ: CYTR  ) was the lucky beneficiary. On Tuesday, CytRx announced that it had been given the OK from the FDA to extend the dosing of aldoxorubicin for soft-tissue sarcomas in phase 3 trials until disease progression. Previously, the trial design was set up for just six treatment cycles then analysis. Clearly, if CytRx is being given the opportunity to extend dosing, the FDA must like what it sees from a safety perspective, and it could give CytRx an opportunity to really extend progression-free survival in its late-stage study. Despite the markets' rough week, CytRx ended it 3% higher.

In Part 2 of "This Week in Biotech," we'll examine two overwhelmingly positive clinical trials, a win-win asset development sale, and look at how plausible takeover rumors could be for one struggling biotech stock.

Want an easy way around the regulatory blues? Check out this top stock pick for 2014!
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2809477, ~/Articles/ArticleHandler.aspx, 8/30/2015 6:59:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
AMAG $65.85 Down -0.14 -0.21%
AMAG Pharmaceutica… CAPS Rating: ****
AMRN $2.23 Up +0.14 +6.70%
Amarin Corp plc (A… CAPS Rating: ****
CYTR $2.39 Up +0.07 +3.02%
CytRx Corp CAPS Rating: **
NVS $98.35 Down -0.29 -0.29%
Novartis CAPS Rating: ****
PTCT $40.62 Down -0.49 -1.19%
PTC Therapeutics,… CAPS Rating: **